Products
Mozistobart Biosimilar Monoclonal Antibody (CD22) for Research
Cat No.: GMP-Bios-INN-1287
Anti-SIGLEC2/CD22 therapeutic antibody (Pre-made Mozistobart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Mozistobart (development code TAC001) is a monoclonal antibody targeting CD22. It is developed by Tallac Therapeutics for solid tumors. It is in Phase I/II clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1287-1mg | 1mg | 3090 |
| GMP-Bios-INN-1287-10mg | 10mg | |
| GMP-Bios-INN-1287-100mg | 100mg | |
| GMP-Bios-INN-1287-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Mozistobart biosimilar, Whole mAb, Anti-SIGLEC2/CD22 Antibody: Anti-CD22/B-cell receptor CD22/B-lymphocyte cell adhesion molecule (BL-CAM)/Sialic acid-binding Ig-like lectin 2 (Siglec-2) therapeutic antibody |
| INN Name | Mozistobart |
| Target | SIGLEC2/CD22 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I/II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2024 |
| Year Recommended | 2024 |
| Companies | Tallac Therapeutics |
| Conditions Approved | na |
| Conditions Active | Solid tumours |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
